BBIO
BridgeBio Pharma IncNASDAQ
Healthcare • Biotechnology
Factor tilt: Large-Cap Blend
$74.29+0.03%
Close Nov 6, 2026
- Market cap
- $14.55B
- 1 month
- +14.2%
- 3 months
- -12.3%
- 1 year
- +18.6%
- 52-week range
- $61.80$90.17
- Dividend
- No dividends on record
- Short interest
- 12.0% of float20M shares · settled Oct 15, 2026 · +1.7% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Sep 30, 2026
- Revenue
- $945.54M
- Net income
- -$570.21M
- Free cash flow
- -$374.31M
- Book value
- —
- Total debt
- $548.43M
- P/E
- —
- Price / sales
- 15.4×
- Price / book
- —
- FCF yield
- -2.6%
- Net margin
- -60.3%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for
Read more
the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
- Website
- bridgebio.com
- Headquarters
- Palo Alto, CA, United States
- Employees
- 999
- Listed
- Jun 27, 2019
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 31, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Sep 2026 | $353.2M | +192.6% | 94.2% | -$11.6M | -$56.7M |
| Jun 2026filed Aug 10, 2026 | $243.7M | +120.4% | 93.8% | -$107.1M | -$152.2M |
| Mar 2026filed May 7, 2026 | $194.5M | +66.8% | 94.6% | -$106.0M | -$164.0M |
| Dec 2025filed Feb 24, 2026 | $154.2M | +2,521.2% | 90.0% | -$185.2M | -$197.2M |
| Sep 2025filed Oct 29, 2025 | $120.7M | +4,318.0% | 94.6% | -$145.2M | -$182.7M |
| Jun 2025filed Aug 5, 2025 | $110.6M | +4,999.9% | 96.7% | -$134.3M | -$181.9M |
| Mar 2025filed Apr 29, 2025 | $116.6M | -44.8% | 97.7% | -$104.4M | -$167.4M |
| Dec 2024filed Feb 20, 2025 | $5.9M | +237.1% | 64.6% | -$226.0M | -$265.1M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 24, 2026 | $502.1M | +126.3% | 94.4% | -$569.1M | -$729.3M |
| Dec 2024filed Feb 20, 2025 | $221.9M | +2,285.3% | 98.3% | -$593.0M | -$535.8M |
| Dec 2023filed Feb 22, 2024 | $9.3M | -88.0% | 73.7% | -$607.4M | -$643.2M |
| Dec 2022filed Feb 23, 2023 | $77.6M | +11.4% | 95.6% | -$512.2M | -$481.2M |
| Dec 2021filed Feb 25, 2022 | $69.7M | +745.1% | 95.5% | -$576.6M | -$562.5M |
| Dec 2020filed Feb 25, 2021 | $8.2M | -79.7% | — | -$474.5M | -$448.7M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched BBIO. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
19,997,556 shares short
+326,264 shares (+1.7%) vs Sep 30, 2026
12% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
19,671,292 shares short
-1,878,057 shares (-8.7%) vs Sep 15, 2026
11.8% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
21,549,349 shares short
-296,550 shares (-1.4%) vs Aug 31, 2026
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
21,845,899 shares short
-1,478,160 shares (-6.3%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
23,324,059 shares short
-18,564 shares (-0.1%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
23,342,623 shares short
-2,408,026 shares (-9.4%) vs Jul 15, 2026
14.3% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind BBIO’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if BBIO is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
83 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Oct 30, 2026
Smart-money 13F trend: distributing (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 4 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
478 filers reported a long position in BBIO for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
45.7%
of the 193.6M shares 13-F filers reported
Moves vs Q1 2026
4 added4 trimmed
1 unchanged · 1 not comparable
Net shares held
-1.1%
across the 9 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | Jupiter Topco LLC | $1.1B · 14.1M shares | 14.1M | — |
| 2 | Kohlberg Kravis Roberts & Co. L.P. | $987.7M · 13.3M shares | 13.3M | Unchanged |
| 3 | FARALLON CAPITAL MANAGEMENT, L.L.C. | $800.1M · 10.7M shares | 10.7M | +14.7% |
| 4 | BlackRock, Inc. | $766.2M · 10.3M shares | 10.3M | -27.6% |
| 5 | VIKING GLOBAL INVESTORS LP | $741M · 9.9M shares | 9.9M | -16% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | $588.3M · 7.9M shares | 7.9M | +1.8% |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | $570.3M · 7.7M shares | 7.7M | -5.2% |
| 8 | WELLINGTON MANAGEMENT GROUP LLP | $395.4M · 5.3M shares | 5.3M | +113.7% |
| 9 | TWO SIGMA INVESTMENTS, LP | $351.7M · 4.7M shares | 4.7M | +51.3% |
| 10 | Aisling Capital Management LP | $341.8M · 4.6M shares | 4.6M | -9.8% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of BBIO file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Oct 27, 2026 | BlackRock, Inc.13G · passive | 5.1% |
| Aug 17, 2026 | KKR Genetic Disorder LP13D · activist · amended | 4.7%under 5% |
| Aug 3, 2026 | FARALLON CAPITAL MANAGEMENT, L.L.C.13G · passive · amended | 5.5% |
| Jul 10, 2026 | VIKING GLOBAL INVESTORS LP13D · activist · amended | 5% |
| May 29, 2026 | Farallon Capital Partners LP13G · passive | 5.2% |
| May 15, 2026 | JANUS HENDERSON GROUP PLC13G · passive · amended | 6.8% |
| Apr 16, 2026 | Kumar Neil13G · passive · amended | 4.6%under 5% |
| Mar 26, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for BBIO
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.